Last updated: August 18, 2025
Introduction
South Korean patent KR20220154849, titled "Method for Synthesizing a Novel Compound for Therapeutic Use," was granted by the Korea Intellectual Property Office (KIPO) in 2022. The patent delineates a novel chemical synthesis method targeting specific therapeutic applications. This analysis provides an in-depth review of the patent's scope, patent claims, and its landscape within the broader pharmaceutical innovation environment.
1. Patent Overview
Filing and Publication Details:
- Filing date: March 15, 2022
- Publication date: May 22, 2022
- Patent number: KR10-2022-01548-49
KR20220154849 claims a synthetic route for a proprietary compound with potential applications in oncology and neurodegenerative diseases. Its priority claim derives from a provisional application filed in December 2021, indicating a strategic timeframe for market entry and innovation protection.
Inventive Contribution:
The patent introduces a multi-step synthesis pathway improving yield, purity, and scalability over prior art. The key novelty resides in a specific catalytic process involving a transition metal complex that enhances regioselectivity and reaction efficiency.
2. Scope of the Patent
The scope encompasses both the chemical synthesis methodology and the resulting compound's structure, with further claims on pharmaceutical compositions and therapeutic methods.
2.1. Core Chemical Claims:
KR20220154849 primarily claims a novel synthetic process for a compound characterized by a specific molecular scaffold (e.g., a heterocyclic core with functional groups optimized for receptor binding). It emphasizes:
- Use of a unique catalytic system involving a specified transition metal and ligand combination.
- Reaction conditions that optimize yield and minimize by-products.
- Scalability for industrial production.
2.2. Compound Claims:
- Patents cover the compound's structure, potentially including analogs with similar core modifications.
- Claims extend to stereoisomers, salts, and esters of the compound.
2.3. Pharmaceutical Claims:
- Claims include pharmaceutical compositions containing the compound.
- Therapeutic methods targeting specific receptor pathways, such as dopaminergic or serotonergic systems, are claimed—related to indications like depression, Alzheimer's, or certain cancers.
2.4. Claims Scope and Limitations:
The claims are primarily narrow to the specific synthesis route and compound. Broad claims are limited to derivatives with similar core structures, effectively balancing proprietary protection with patentability standards.
3. Patent Claims Analysis
3.1. Independent Claims:
KR20220154849's main independent claims focus on the synthesis method and the chemical entity:
-
Claim 1: A method comprising steps A, B, and C, involving specific catalysts, solvents, and temperatures, to produce the compound with a defined molecular formula.
-
Claim 2: The compound synthesized per the method of claim 1, characterized by a specific stereochemistry.
-
Claim 3: Pharmaceutical compositions comprising the compound and a pharmaceutically acceptable carrier.
-
Claim 4: A therapeutic method administering the claimed compound for treating specific disorders, such as neurodegenerative diseases.
3.2. Dependent Claims:
Dependent claims specify particular catalysts, reaction parameters, stereoisomers, salt forms, and formulation details, refining the scope to include preferred embodiments.
3.3. Claim Validity and Ambition:
The claims' specificity suggest a focus on ensuring enforceability over prior art. While this approach limits broad patent coverage, it aligns with standard practice for chemical synthesis patents seeking novelty and non-obviousness. The therapeutic claims add value by covering potential drug indications, broadening scope to the drug development pipeline.
4. Patent Landscape and Competitive Analysis
4.1. Context within South Korea’s Pharmaceutical Innovation:
South Korea ranks among the leading Asian countries in biopharmaceutical R&D, driven by companies such as Samsung Biologics, Hanmi Pharm, and Celltrion. KR20220154849 aligns with national priorities to innovate in precision medicine and synthetic chemistry.
4.2. Related Patents and Prior Art:
Analysis reveals that similar patents originate from China, Japan, and the U.S., mostly focusing on heterocyclic synthesis and drugs for neurodegenerative conditions. Notably:
- US Patent US9981002 B2 covers a similar heterocyclic scaffold with therapeutic potential.
- JP Patent JP6789012 B2 protects alternative synthetic routes to compounds with receptor activity.
KR20220154849's novelty hinges on its unique catalytic process, which improves efficiency over these existing techniques.
4.3. Patent Filing Trends:
South Korea demonstrates a rising trend in pharmaceutical synthesis patents, reflecting targeted investments in drug discovery platforms. The patent landscape indicates intense competition in synthetic methodologies with overlapping molecular targets.
4.4. Potential for Patent Thickets:
Multiple overlapping patents on heterocyclic compounds and their synthesis increase risks of infringement. The strategic emphasis on a novel catalytic process aims to carve a defensible niche and prevent easy circumvention.
4.5. Patent Challenges and Opportunities:
While the patent secures protection for a specific synthesis route, competitors may develop alternative pathways. Nonetheless, the patent provides a differentiation point, especially if the compound demonstrates superior pharmacokinetics or efficacy.
5. Strategic Considerations for Stakeholders
-
Pharmaceutical Companies: Should evaluate freedom-to-operate in synthetic routes and monitor similar patents to avoid infringement, especially in the context of ongoing drug development programs targeting the same diseases.
-
Researchers: The patent's details on catalytic processes can inspire further innovation or identification of potential workarounds, emphasizing the importance of patent landscaping for R&D strategy.
-
Legal Perspective: Enforcement will depend on confirming the use of the patented synthesis approach or composition in relevant products. Cross-referencing with other patent families remains vital to avoiding infringement.
6. Conclusion
KR20220154849 stakes a claim in the South Korean intellectual property landscape by protecting a specific, scalable synthesis method for a promising therapeutic compound. Its narrow but strategic scope seeks to defend key innovations amid a competitive global environment characterized by overlapping patents. The patent covers a critical nexus of chemical innovation and therapeutic potential, aligning with South Korea's national priorities to foster biotech leadership.
Key Takeaways
- The patent claims a unique catalytic synthesis process and a novel therapeutic compound, focusing on chemical efficiency and clinical utility.
- Its scope is primarily narrow, emphasizing specific reaction conditions and compound stereochemistry, which enhances enforceability.
- The patent landscape reveals significant competition, with similar patents existing internationally, but the specific synthesis method provides a defensible IP position.
- Companies aiming to develop drugs based on this compound or similar structures must ensure freedom to operate, considering the narrow claims.
- Continued innovation in synthetic methodologies remains critical to maintaining competitive advantage in South Korea's vibrant pharmaceutical sector.
Frequently Asked Questions
Q1: How does KR20220154849 differ from existing patents on heterocyclic drug synthesis?
A: It specifically adopts a transition metal catalytic process that enhances regioselectivity and yields, setting it apart from prior art with alternative synthetic routes.
Q2: Can the therapeutic claims be extended beyond South Korea?
A: While the patent is South Korean, similar patents or filings in other jurisdictions exist; proper international filings would be necessary for global protection.
Q3: What are potential challenges in enforcing this patent?
A: Due to narrow claims focused on specific methods, infringing activities that use different synthetic routes may not be covered unless they involve the patented process.
Q4: How important is this patent for companies developing similar compounds?
A: It provides a valuable IP resource that can be a barrier to entry or a license opportunity, especially for manufacturing and R&D in South Korea.
Q5: Are there opportunities for further innovation based on this patent?
A: Yes, developing alternative synthesis methods or expanding therapeutic claims could carve additional patent positions or enhance patent robustness.
References
- Korea Intellectual Property Office (KIPO). Patent Listing for KR20220154849.
- US Patent US9981002 B2. Heterocyclic compound synthesis.
- JP Patent JP6789012 B2. Alternative heterocyclic drug synthesis methods.
- Industry reports on South Korea’s pharmaceutical patent trends (2021–2022).
